Potent cdk1 inhibitor (IC50
= 25 nM). Reduces Akt phosphorylation and increases mitochondrial damage in leukemia cells in vitro
in combination with LY 294002
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu et al.
Cancer Res., 2013;63:1822
Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet et al.
J.Comput.Aided Mol.Des., 2000;14:403